Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Mar. 09, 2018 | Jun. 30, 2017 | |
Document Information [Line Items] | |||
Entity Registrant Name | PROTEON THERAPEUTICS INC | ||
Entity Central Index Key | 1,359,931 | ||
Trading Symbol | prto | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Common Stock, Shares Outstanding (in shares) | 17,674,729 | ||
Entity Public Float | $ 16.3 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2017 | ||
Document Fiscal Year Focus | 2,017 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Current assets: | ||
Cash and cash equivalents | $ 21,170 | $ 36,392 |
Available-for-sale investments | 20,971 | 4,925 |
Prepaid expenses and other current assets | 1,339 | 1,438 |
Total current assets | 43,480 | 42,755 |
Property and equipment, net | 259 | 372 |
Other non-current assets | 240 | 393 |
Total assets | 43,979 | 43,520 |
Current liabilities: | ||
Accounts payable | 291 | 556 |
Accrued expenses | 8,949 | 4,523 |
Total current liabilities | 9,240 | 5,079 |
Total liabilities | 9,240 | 5,079 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Preferred Stock | 0 | 0 |
Common stock, $0.001 par value, 100,000,000 shares authorized at December 31, 2017 and 2016; 17,674,729 and 16,603,559 shares issued and outstanding at December 31, 2017 and 2016, respectively | 18 | 17 |
Additional paid-in capital | 202,953 | 198,201 |
Accumulated deficit | (189,741) | (159,777) |
Accumulated other comprehensive loss | (14) | |
Total stockholders’ equity | 34,739 | 38,441 |
Total liabilities and stockholders’ equity | 43,979 | 43,520 |
Series A Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred Stock | $ 21,523 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2017 | Dec. 31, 2016 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 17,674,729 | 16,603,559 |
Common stock, shares oustanding (in shares) | 17,674,729 | 16,603,559 |
Series A Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 22,000 | 0 |
Preferred stock, shares issued (in shares) | 22,000 | 0 |
Preferred stock, shares outstanding (in shares) | 22,000 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Operating expenses: | |||
Research and development | $ 21,686 | $ 18,869 | $ 12,381 |
General and administrative | 8,676 | 9,836 | 8,489 |
Total operating expenses | 30,362 | 28,705 | 20,870 |
Loss from operations | (30,362) | (28,705) | (20,870) |
Other income (expense): | |||
Investment income | 259 | 193 | 144 |
Other income (expense), net | 139 | (14) | (651) |
Total other income (expense) | 398 | 179 | (507) |
Net loss | (29,964) | (28,526) | (21,377) |
Foreign currency translation adjustment | 6 | 0 | |
Unrealized (loss) gain on available-for-sale investments | (20) | 11 | (5) |
Comprehensive loss | (29,978) | (28,515) | (21,382) |
Reconciliation of net loss to net loss attributable to common stockholders: | |||
Net loss | 29,964 | 28,526 | 21,377 |
Accretion of convertible preferred stock to redemption value | (6,747) | ||
Net loss attributable to common stockholders | $ (36,711) | $ (28,526) | $ (21,377) |
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) | $ (2.13) | $ (1.72) | $ (1.30) |
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted (in shares) | 17,274,326 | 16,561,799 | 16,464,123 |
Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense: | |||
Allocated share-based compensation | $ 3,227 | $ 3,343 | $ 2,164 |
Included in other expense, above, are the following amounts from forward foreign currency contracts: | |||
Realized losses from forward foreign currency contracts | (61) | (52) | |
Unrealized gains (losses) from forward foreign currency contracts | 127 | (537) | |
Total | 66 | (589) | |
Research and Development Expense [Member] | |||
Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense: | |||
Allocated share-based compensation | 1,109 | 1,114 | 650 |
General and Administrative Expense [Member] | |||
Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense: | |||
Allocated share-based compensation | $ 2,118 | $ 2,229 | $ 1,514 |
Statements of Stockholders' Equ
Statements of Stockholders' Equity - USD ($) $ in Thousands | Series A Preferred Stock [Member]Preferred Stock [Member] | Series A Preferred Stock [Member]Additional Paid-in Capital [Member] | Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2014 | 16,448,455 | |||||||
Balance at Dec. 31, 2014 | $ 16 | $ 192,324 | $ (109,874) | $ (6) | $ 82,460 | |||
Exercise of common stock options (in shares) | 45,413 | |||||||
Exercise of common stock options | 88 | 88 | ||||||
Issuance of common stock upon ESPP purchase (in shares) | 7,632 | |||||||
Issuance of common stock upon ESPP purchase | 75 | 75 | ||||||
Stock-based compensation expense | 2,164 | 2,164 | ||||||
Unrealized (loss) gain on available-for-sale investments | (5) | (5) | ||||||
Net loss | (21,377) | (21,377) | ||||||
Balance (in shares) at Dec. 31, 2015 | 16,501,500 | |||||||
Balance at Dec. 31, 2015 | $ 16 | 194,651 | (131,251) | (11) | 63,405 | |||
Exercise of common stock options (in shares) | 97,521 | |||||||
Exercise of common stock options | $ 1 | 196 | 197 | |||||
Issuance of common stock upon ESPP purchase (in shares) | 4,538 | |||||||
Issuance of common stock upon ESPP purchase | 11 | 11 | ||||||
Stock-based compensation expense | 3,343 | 3,343 | ||||||
Unrealized (loss) gain on available-for-sale investments | 11 | 11 | ||||||
Net loss | (28,526) | (28,526) | ||||||
Balance (in shares) at Dec. 31, 2016 | 16,603,559 | |||||||
Balance at Dec. 31, 2016 | $ 17 | 198,201 | (159,777) | $ 38,441 | ||||
Exercise of common stock options (in shares) | 74,001 | 74,001 | ||||||
Exercise of common stock options | 108 | $ 108 | ||||||
Issuance of common stock upon ESPP purchase (in shares) | 100,358 | |||||||
Issuance of common stock upon ESPP purchase | 130 | 130 | ||||||
Stock-based compensation expense | 3,227 | 3,227 | ||||||
Unrealized (loss) gain on available-for-sale investments | (20) | |||||||
Net loss | (29,964) | (29,964) | ||||||
Issuance of stock, net of issuance costs (in shares) | 22,000 | 896,811 | ||||||
Issuance of stock, net of issuance costs | $ 14,776 | $ 6,747 | $ 21,523 | $ 1 | 1,287 | 1,288 | ||
Accretion of Series A Convertible Preferred Stock | $ 6,747 | (6,747) | ||||||
Other comprehensive loss | (14) | (14) | ||||||
Balance (in shares) at Dec. 31, 2017 | 22,000 | 17,674,729 | ||||||
Balance at Dec. 31, 2017 | $ 21,523 | $ 18 | $ 202,953 | $ (189,741) | $ (14) | $ 34,739 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Operating activities | |||
Net loss | $ (29,964) | $ (28,526) | $ (21,377) |
Reconciliation of net loss to net cash used in operating activities: | |||
Depreciation | 148 | 123 | 57 |
Amortization of premium/discount on available-for-sale securities | (2) | 131 | 651 |
Unrealized (gain) loss on forward foreign currency contracts included in net income | (127) | 537 | |
Foreign currency remeasurement (gain)/loss | (173) | 76 | 75 |
Stock-based compensation | 3,227 | 3,343 | 2,164 |
Changes in: | |||
Prepaid expenses and other assets | 297 | 246 | (899) |
Interest receivable | (46) | (26) | (32) |
Accounts payable and accrued expenses | 4,161 | 1,073 | 1,258 |
Net cash used in operating activities | (22,352) | (23,687) | (17,566) |
Investing activities | |||
Purchases of available-for-sale investments | (32,942) | (39,756) | (88,644) |
Proceeds from maturities of available-for-sale investments | 16,878 | 59,943 | 75,505 |
Proceeds from sale of available-for-sale investments | 2,006 | ||
Purchase of property and equipment | (35) | (271) | (198) |
Net cash (used in) provided by investing activities | (16,099) | 19,916 | (11,331) |
Financing activities | |||
Proceeds from issuance of common stock, net of issuance costs | 1,288 | ||
Proceeds from the issuance of Series A Convertible Preferred Stock, net of issuance costs | 21,523 | ||
Proceeds from issuance of common stock under ESPP | 130 | 11 | 75 |
Exercise of stock options | 108 | 197 | 88 |
Net cash provided by financing activities | 23,049 | 208 | 163 |
Effect of exchange rate changes on cash | 180 | (76) | (75) |
Decrease in cash and cash equivalents | (15,222) | (3,639) | (28,809) |
Cash and cash equivalents, beginning of period | 36,392 | 40,031 | 68,840 |
Cash and cash equivalents, end of period | 21,170 | 36,392 | 40,031 |
Supplemental disclosure of non-cash investing and financing activities | |||
Accretion of convertible preferred stock | $ 6,747 |
Note 1 - Organization and Opera
Note 1 - Organization and Operations | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization and Operations The Company Proteon Therapeutics, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on the development of novel, first June 2001 March 24, 2006. The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has not third As of December 31, 2017, $42.1 fourth 2019. $189.7 December 31, 2017. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies At-The-Market Equity Offering Program On November 12, 2015, 3 $40 January 12, 2016. 3% March 16, 2017 I.B.6 3, may December 31, 2017, 896,811 $1.4 December 31, 2017, $0.1 Series A Preferred Financing On June 22, 2017, 22,000 $0.001 $1,000 $22.0 August 2, 2017 ( 8 On August 2, 2017, August 3, 2017, 3 August 21, 2017. Basis of Presentation, Principles of Consolidation and Use of Estimates The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not may Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company's chief operating decision maker view the Company's operations and manage its business in one one Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, available-for-sale investments, forward foreign currency contracts (see Note 3 820, Fair Value Measurement and Disclosures not one three Level 1—Valuations Level 2—Valuations not Level 3—Valuations To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents, available-for-sale investments and forward foreign currency contracts (see Note 3 no December 31, 2017 2016. no December 31, 2017 2016. Derivative Financial Instruments The Company enters into forward foreign currency contracts to mitigate its exposure to fluctuations in the exchange rates between the Swiss Franc and the U.S. dollar (see Note 4 not Recent Accounting Pronouncements In May 2014, 2014 09, “Revenue from Contracts with Customers” 2014 09” January 1, 2018, no December 15, 2016, may not In February 2016, 2016 02, Leases (Topic 842 2016 02” 2016 02 December 15, 2018, 2016 02 In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718 2016 09” 2016 09 December 15, 2016, 2016 09 March 31, 2017. $0.6 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15” eight December 15, 2017, first 2019 not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 2017 09” 2017 09, not 2017 09 December 15, 2017. not Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of 90 Short-Term Investments The Company classifies its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the consolidated statements of operations and comprehensive loss and as a separate component of stockholders' equity (deficit). The Company invests its excess cash balances primarily in government debt securities and money market funds with strong credit ratings and maturities of less than one no December 31, 2017, 2016 2015. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the year in which the other-than-temporary decline occurred. There have been no December 31, 2017, 2016 2015, not Concentrations of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and short-term investments. The Company's cash and cash equivalents are held in accounts with financial institutions that management believes are creditworthy. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts at times may not not no Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs that do not Asset Estimated Useful Life (in years) Computer equipment and software 3 Furniture, fixtures and other 5 Laboratory equipment 7 Research and Development Costs Research and development costs are charged to expense as incurred in performing research and development activities. The costs include employee compensation costs, facilities and overhead, clinical study and related clinical manufacturing costs, regulatory and other related costs. Nonrefundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards to employees and directors in accordance with FASB ASC Topic 718, Compensation-Stock Compensation 718” 718 718 505, Equity The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate, (d) expected dividends and (e) the estimated fair value of its Common Stock on the measurement date. Due to the lack of company specific historical and implied volatility data of its Common Stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected term of the stock based awards. The Company computes historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not 2, Use of Estimates Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, 740” not not may not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not December 31, 2017 2016, not 11 Net Income (Loss) per Share Attributable to Common Stockholders Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The Company follows the two two two not Comprehensive Loss Comprehensive loss consists of net income or loss and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources. The Company's net loss equals comprehensive loss, net of any changes in the unrealized gains and losses of the Company's short-term investments, held as available-for-sale, and foreign currency translation for all periods presented. Subsequent Events The Company considers events or transactions that occur after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in the financial statements. The Company has completed an evaluation of all subsequent events after the consolidated balance sheet date of December 31, 2017 December 31, 2017 not |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | Below is a summary of assets and liabilities measured at fair value (in thousands): As of December 31, 2017 Quoted Prices Significant Significant Total Assets Cash equivalents $ 11,662 $ - $ - $ 11,662 Government securities 20,971 - - 20,971 Total $ 32,633 $ - $ - $ 32,633 As of December 31, 2016 Quoted Prices Significant Significant Total Assets Cash equivalents $ 28,876 $ - $ - $ 28,876 Government securities 4,925 - - 4,925 Total $ 33,801 $ - $ - $ 33,801 As of December 31, 2017, 2016, 90 Available-for-sale securities at December 31, 2017 2016 Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2017 Government securities (Due within 1 year) $ 20,991 $ - $ (20 ) $ 20,971 $ 20,991 $ - $ (20 ) $ 20,971 December 31, 2016 Government securities (Due within 1 year) $ 4,924 $ 1 $ - $ 4,925 $ 4,924 $ 1 $ - $ 4,925 |
Note 4 - Derivative Financial I
Note 4 - Derivative Financial Instruments | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Derivative Instruments and Hedging Activities Disclosure [Text Block] | 4. Derivative Financial Instruments Beginning in May 2015 2016, not December 31, 2016, December 31, 2016, no |
Note 5 - Property and Equipment
Note 5 - Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5. Property and Equipment, net Property and equipment, net consists of the following (in thousands): As of December 31, 2017 2016 Computer equipment and software $ 192 $ 141 Furniture, fixtures, and other 302 318 Laboratory equipment 477 478 971 937 Accumulated depreciation (712 ) (565 ) Property and equipment, net $ 259 $ 372 Depreciation expense for the years ended December 31, 2017, 2016 2015 $0.1 $0.1 $0.1 |
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued Expenses Accrued expenses consist of the following (in thousands): As of December 31, 2017 2016 Payroll and employee-related costs $ 1,318 $ 1,139 Contracted service costs 7,218 2,891 Professional fees and other 413 493 Total $ 8,949 $ 4,523 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 7. Commitments and Contingencies Significant Contracts and Agreements In February 2002, 2.5% December 31, 2017 not no In July 2015, December 31, 2017, 7.6 $7.8 three July 2017 one 2019. December 31, 2017, three July 2017 Operating Leases The Company has various non-cancellable operating leases for facilities and office equipment that expire at various dates through 2019. August 2017, July 13, 2009 ( fifteen 15 June 30, 2018 September 30, 2019 2,552 7,500 200 one six December 31, 2017, 2016 2015 $0.2 Future minimum payments required under operating leases as of December 31, 2017 Year Ending December 31: Amount 2018 $ 270 2019 207 Total minimum lease payments $ 477 In addition to the base rent, the Company is also responsible for its share of operating expenses and real estate taxes, in accordance with the terms of the lease agreement. As of December 31, 2017, $22,000 Restricted cash related to facilities leases At December 31, 2017 2016, $22,000 $14,000, December 31, 2017 2016, $22,000 $14,000, |
Note 8 - Series A Preferred Fin
Note 8 - Series A Preferred Financing | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 8. Series A Preferred Financing On August 2, 2017, 22,000 $0.001 $1,000 $22.0 June 22, 2017. $0.5 1,005 $0.9949 13 9.985% Upon issuance, each share of Series A Preferred included an embedded beneficial conversion feature as the market price of the Company’s Common Stock on the date of issuance of the Series A Preferred was $1.30 $6.7 not The Company evaluated the Series A Preferred for liability or equity classification in accordance with the provisions of ASC 480, not not not not 480 no not Dividends Holders of the Series A Preferred Stock are entitled to receive dividends, if and when declared by the Board of Directors. Liquidation Preference Holders of the Series A Preferred Stock have preference in the event of a liquidation or dissolution of the Company equal to $0.001 Thereafter, the Holders of the shares of Series A Preferred Stock shall share ratably in any distributions and payments of any remaining assets of the Company, on an as converted basis, with the holders of Common Stock. Voting Rights Except for matters with specific voting rights as provided in the Series A Preferred Stock Purchase Agreement, the Holders of shares of Series A Preferred Stock have no |
Note 9 - Common Stock
Note 9 - Common Stock | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Common Stock [Text Block] | 9. Common Stock General At December 31, 2017, 100,000,000 $0.001 17,674,729 Reserved for Future Issuance The Company has the following shares of Common Stock reserved for future issuance: December 31, December 31, 2017 2016 Conversion of Series A Preferred Stock 22,112,775 - Stock-based compensation awards 3,572,457 2,982,470 Employee Stock Purchase Plan 192,463 292,821 Total 25,877,695 3,275,291 |
Note 10 - Stock-based Compensat
Note 10 - Stock-based Compensation | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 10. Stock-based Compensation On August 21, 2014, 2014 “2014 2014 “2014 2006 “2006 October 3, 2014, 2014 July 31, 2017. The Plans provide for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. Under the 2006 no 704,000 2014 2014 2014 January 1, January 1, 2015 four December 31 January 1st. Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the Plans. Options granted by the Company typically vest over three four 2006 ten 2014 Stock-based compensation expense Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company’s consolidated statements of operations as follows (in thousands): Year Ended December 31, 2017 2016 2015 Research and development $ 1,109 $ 1,114 $ 650 General and administrative 2,118 2,229 1,514 Total $ 3,227 $ 3,343 $ 2,164 The Company estimates the fair value of each employee stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions regarding the fair value of the underlying Common Stock on each measurement date: Year Ended December 31, 2017 2016 2015 Weighted average expected volatility 94.5 % 84.4 % 79.8 % Expected term (in years) 6.06 6.05 6.11 Risk free interest rate 2.09 % 1.45 % 1.76 % Expected dividend yield 0 % 0 % 0 % Stock options issued to non-employees are accounted for using the fair value method of accounting; they are periodically revalued as the options vest and are recognized as expense over the related service period. The total expense related to all options granted to non-employees for the years ended December 31, 2017, 2016 2015 $0, $0 $2,000, Stock Options The following table summarizes stock option activity for employees and non-employees: Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2016 2,166,254 $ 8.55 7.1 $ 124 Granted 719,337 $ 1.99 Exercised (74,001 ) $ 1.45 Forfeited (30,272 ) $ 10.69 Expired (100,246 ) $ 2.60 Outstanding at December 31, 2017 2,681,072 $ 7.18 6.8 $ 121 Exercisable at December 31, 2017 1,495,789 $ 8.18 5.9 $ 85 Vested or expected to vest at December 31, 2017 (1) 2,681,072 $ 7.18 6.8 $ 121 ____________________ ( 1 December 31, 2017 December 31, 2017. During the year ended December 31, 2017, 719,337 $1.99. December 31, 2016, 132,495 $7.11 $5.08. December 31, 2015, 1,010,256 $9.34 The total intrinsic value of options exercised in the years ended December 31, 2017 2016 $27,000 $0.6 December 31, 2017, $4.2 1.95 Employee Stock Purchase Plan The 2014 140,500 January 1, January 1, 2015 January 1, 2024, one 281,000 January 1st. December 31, 2017, 2014 304,991 no January 1, 2018. sixth 2014 July 1, 2017 December 31, 2017. December 31, 2017 2016, 100,358 4,538 2014 192,463 December 31, 2017. $0.1 $0.1 2014 December 31, 2017 2016, |
Note 11 - Income Taxes
Note 11 - Income Taxes | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 11. Income Taxes The components of income from operations before income taxes are as follows (in thousands): Year Ended December 31, 2017 2016 2015 Domestic $ (24,803 ) $ (15,860 ) $ (21,377 ) Foreign (5,161 ) (12,666 ) - Loss before income taxes $ (29,964 ) $ (28,526 ) $ (21,377 ) For the years ended December 31, 2017, 2016, 2015, not A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations is as follows (in thousands): Year Ended December 31, 2017 2016 2015 Income tax benefit using U.S. federal statutory rate $ (10,186 ) $ (9,696 ) $ (7,315 ) Permanent differences 4 430 260 Stock Compensation - Perm Items 689 - - R&D Credit -Perm Items 1,751 1,437 1,310 State income taxes, net of federal benefit (853 ) (498 ) (808 ) Tax credits (5,495 ) (4,846 ) (4,219 ) Change in valuation allowance (54,319 ) 8,804 9,782 Foreign rate differential 1,752 4,304 - Rate change 2,202 - - 382 Limitation 64,975 - - Other (520 ) 65 990 $ - $ - $ - The significant components of the Company's deferred tax assets are as follows (in thousands): Year Ended December 31, 2017 2015 2014 Net operating loss carryforwards $ 2,651 $ 42,156 $ 34,488 Federal and state tax credits 2,244 21,223 16,404 Accrued expenses 399 544 27 Patents 191 360 443 Stock-based compensation 1,262 1,353 596 Other 202 320 276 6,949 65,956 52,234 Valuation allowance (6,949 ) (65,956 ) (52,234 ) Net deferred tax asset $ - $ - $ - Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company's history of operating losses, management of the Company has concluded that it is more likely than not not December 31, 2017, 2016, 2015. On December 22, 2017, 34% 21%. $2.2 no not 2017 may no one Net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the "IRS") and may three 50% 382 383 “§382 may August 2, 2017, $22.0 §382 §383 August 2, 2017 August 2, 2017 $107.3 $34.1 $23.8 $5.0 $2.1 As a result of current year activity, the valuation allowance increased by approximately $13.1 December 31, 2017. $65.0 §382 $2.2 $54.1 $8.8 December 31, 2016, $9.8 December 31, 2015, Subject to the limitations described above, as of December 31, 2017, 2016, 2015, $10.6 $101.4 $94.2 2037. December 31, 2017, 2016, 2015, $6.8 $53.0 $46.4 2032 2037. December 31, 2017, 2016 2015, $2.3 $21.8 $16.9 2022 2037. The Company had no December 31, 2017, 2016, 2015. The Company is subject to U.S. federal income tax and primarily Massachusetts state income tax. The statute of limitations for assessment by the IRS and state tax authorities is open for tax years ending December 31, 2014 2017, 2014 may no The Company has adopted ASU 2016 09, March 31, 2017. $0.6 |
Note 12 - Net Loss Per Share At
Note 12 - Net Loss Per Share Attributable to Common Stockholders | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 12. Net Loss per Share Attributable to Common Stockholders As described in Note 2, December 31, 2017, 2016 2015 no two The following Common Stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect: Year Ended December 31, 2017 2016 2015 Outstanding stock options 2,681,072 2,166,254 2,200,369 Convertible preferred stock 22,112,775 - - 24,793,847 2,166,254 2,200,369 |
Note 13 - Quarterly Financial I
Note 13 - Quarterly Financial Information (Unaudited, in Thousands, Except Share and Per Share Data) | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Quarterly Financial Information [Text Block] | 13. Quarterly Financial Information (unaudited, in thousands, except share and per share data) The following table contains selected quarterly financial information from 2017 2016. not Three Months Ended March 31, June 30, September 30, December 31, Operating expenses $ 6,480 $ 5,986 $ 12,306 $ 5,590 Net loss attributable to common stockholders (6,498 ) (5,608 ) (19,054 ) (5,551 ) Net loss per share attributable to common stockholders: Basic and Diluted $ (0.39 ) $ (0.33 ) $ (1.08 ) $ (0.33 ) Weighted-average common shares outstanding used in net loss per share attributable to common stockholders: Basic and Diluted 16,636,201 17,207,672 17,619,418 (a) 17,619,418 Three Months Ended March 31, June 30, September 30, December 31, Operating expenses $ 6,819 $ 7,854 $ 7,166 $ 6,866 Net loss attributable to common stockholders (6,552 ) (7,905 ) (7,107 ) (6,962 ) Net loss per share attributable to common stockholders: Basic and Diluted $ (0.40 ) $ (0.48 ) $ (0.43 ) $ (0.42 ) Weighted-average common shares outstanding used in net loss per share attributable to common stockholders: Basic and Diluted 16,507,586 16,561,239 16,582,276 16,595,502 (a) Adjusted to correct an immaterial error in the weighted-average share calculation in the Company's Form 10 September 30, 2017. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
At-the-market Equity Offering Program [Policy Text Block] | At-The-Market Equity Offering Program On November 12, 2015, 3 $40 January 12, 2016. 3% March 16, 2017 I.B.6 3, may December 31, 2017, 896,811 $1.4 December 31, 2017, $0.1 |
Convertible Preferred Stock, Policy [Policy Text Block] | Series A Preferred Financing On June 22, 2017, 22,000 $0.001 $1,000 $22.0 August 2, 2017 ( 8 On August 2, 2017, August 3, 2017, 3 August 21, 2017. Basis of Presentation, Principles of Consolidation and Use of Estimates The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not may |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation, Principles of Consolidation and Use of Estimates The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not may |
Segment Reporting, Policy [Policy Text Block] | Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company's chief operating decision maker view the Company's operations and manage its business in one one |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, available-for-sale investments, forward foreign currency contracts (see Note 3 820, Fair Value Measurement and Disclosures not one three Level 1—Valuations Level 2—Valuations not Level 3—Valuations To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents, available-for-sale investments and forward foreign currency contracts (see Note 3 no December 31, 2017 2016. no December 31, 2017 2016. |
Derivatives, Policy [Policy Text Block] | Derivative Financial Instruments The Company enters into forward foreign currency contracts to mitigate its exposure to fluctuations in the exchange rates between the Swiss Franc and the U.S. dollar (see Note 4 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In May 2014, 2014 09, “Revenue from Contracts with Customers” 2014 09” January 1, 2018, no December 15, 2016, may not In February 2016, 2016 02, Leases (Topic 842 2016 02” 2016 02 December 15, 2018, 2016 02 In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718 2016 09” 2016 09 December 15, 2016, 2016 09 March 31, 2017. $0.6 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15” eight December 15, 2017, first 2019 not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 2017 09” 2017 09, not 2017 09 December 15, 2017. not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of 90 |
Investment, Policy [Policy Text Block] | Short-Term Investments The Company classifies its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the consolidated statements of operations and comprehensive loss and as a separate component of stockholders' equity (deficit). The Company invests its excess cash balances primarily in government debt securities and money market funds with strong credit ratings and maturities of less than one no December 31, 2017, 2016 2015. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. When the Company determines that a decline in the fair value below its cost basis is other-than-temporary, the Company recognizes an impairment loss in the year in which the other-than-temporary decline occurred. There have been no December 31, 2017, 2016 2015, not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and short-term investments. The Company's cash and cash equivalents are held in accounts with financial institutions that management believes are creditworthy. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts at times may not not no |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs that do not Asset Estimated Useful Life (in years) Computer equipment and software 3 Furniture, fixtures and other 5 Laboratory equipment 7 |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs Research and development costs are charged to expense as incurred in performing research and development activities. The costs include employee compensation costs, facilities and overhead, clinical study and related clinical manufacturing costs, regulatory and other related costs. Nonrefundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards to employees and directors in accordance with FASB ASC Topic 718, Compensation-Stock Compensation 718” 718 718 505, Equity The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate, (d) expected dividends and (e) the estimated fair value of its Common Stock on the measurement date. Due to the lack of company specific historical and implied volatility data of its Common Stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected term of the stock based awards. The Company computes historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not 2, Use of Estimates |
Income Tax, Policy [Policy Text Block] | Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, 740” not not may not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not December 31, 2017 2016, not 11 |
Earnings Per Share, Policy [Policy Text Block] | Net Income (Loss) per Share Attributable to Common Stockholders Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The Company follows the two two two not |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss Comprehensive loss consists of net income or loss and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources. The Company's net loss equals comprehensive loss, net of any changes in the unrealized gains and losses of the Company's short-term investments, held as available-for-sale, and foreign currency translation for all periods presented. |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events The Company considers events or transactions that occur after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in the financial statements. The Company has completed an evaluation of all subsequent events after the consolidated balance sheet date of December 31, 2017 December 31, 2017 not |
Note 2 - Summary of Significa21
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Property Plant and Equipment Useful Lives [Table Text Block] | Asset Estimated Useful Life (in years) Computer equipment and software 3 Furniture, fixtures and other 5 Laboratory equipment 7 |
Note 3 - Fair Value Measureme22
Note 3 - Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | As of December 31, 2017 Quoted Prices Significant Significant Total Assets Cash equivalents $ 11,662 $ - $ - $ 11,662 Government securities 20,971 - - 20,971 Total $ 32,633 $ - $ - $ 32,633 As of December 31, 2016 Quoted Prices Significant Significant Total Assets Cash equivalents $ 28,876 $ - $ - $ 28,876 Government securities 4,925 - - 4,925 Total $ 33,801 $ - $ - $ 33,801 |
Available-for-sale Securities [Table Text Block] | Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2017 Government securities (Due within 1 year) $ 20,991 $ - $ (20 ) $ 20,971 $ 20,991 $ - $ (20 ) $ 20,971 December 31, 2016 Government securities (Due within 1 year) $ 4,924 $ 1 $ - $ 4,925 $ 4,924 $ 1 $ - $ 4,925 |
Note 5 - Property and Equipme23
Note 5 - Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | As of December 31, 2017 2016 Computer equipment and software $ 192 $ 141 Furniture, fixtures, and other 302 318 Laboratory equipment 477 478 971 937 Accumulated depreciation (712 ) (565 ) Property and equipment, net $ 259 $ 372 |
Note 6 - Accrued Expenses (Tabl
Note 6 - Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | As of December 31, 2017 2016 Payroll and employee-related costs $ 1,318 $ 1,139 Contracted service costs 7,218 2,891 Professional fees and other 413 493 Total $ 8,949 $ 4,523 |
Note 7 - Commitments and Cont25
Note 7 - Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Year Ending December 31: Amount 2018 $ 270 2019 207 Total minimum lease payments $ 477 |
Note 9 - Common Stock (Tables)
Note 9 - Common Stock (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Common Stock Reserved for Future Issuance [Table Text Block] | December 31, December 31, 2017 2016 Conversion of Series A Preferred Stock 22,112,775 - Stock-based compensation awards 3,572,457 2,982,470 Employee Stock Purchase Plan 192,463 292,821 Total 25,877,695 3,275,291 |
Note 10 - Stock-based Compens27
Note 10 - Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Year Ended December 31, 2017 2016 2015 Research and development $ 1,109 $ 1,114 $ 650 General and administrative 2,118 2,229 1,514 Total $ 3,227 $ 3,343 $ 2,164 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended December 31, 2017 2016 2015 Weighted average expected volatility 94.5 % 84.4 % 79.8 % Expected term (in years) 6.06 6.05 6.11 Risk free interest rate 2.09 % 1.45 % 1.76 % Expected dividend yield 0 % 0 % 0 % |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2016 2,166,254 $ 8.55 7.1 $ 124 Granted 719,337 $ 1.99 Exercised (74,001 ) $ 1.45 Forfeited (30,272 ) $ 10.69 Expired (100,246 ) $ 2.60 Outstanding at December 31, 2017 2,681,072 $ 7.18 6.8 $ 121 Exercisable at December 31, 2017 1,495,789 $ 8.18 5.9 $ 85 Vested or expected to vest at December 31, 2017 (1) 2,681,072 $ 7.18 6.8 $ 121 |
Note 11 - Income Taxes (Tables)
Note 11 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Year Ended December 31, 2017 2016 2015 Domestic $ (24,803 ) $ (15,860 ) $ (21,377 ) Foreign (5,161 ) (12,666 ) - Loss before income taxes $ (29,964 ) $ (28,526 ) $ (21,377 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2017 2016 2015 Income tax benefit using U.S. federal statutory rate $ (10,186 ) $ (9,696 ) $ (7,315 ) Permanent differences 4 430 260 Stock Compensation - Perm Items 689 - - R&D Credit -Perm Items 1,751 1,437 1,310 State income taxes, net of federal benefit (853 ) (498 ) (808 ) Tax credits (5,495 ) (4,846 ) (4,219 ) Change in valuation allowance (54,319 ) 8,804 9,782 Foreign rate differential 1,752 4,304 - Rate change 2,202 - - 382 Limitation 64,975 - - Other (520 ) 65 990 $ - $ - $ - |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | Year Ended December 31, 2017 2015 2014 Net operating loss carryforwards $ 2,651 $ 42,156 $ 34,488 Federal and state tax credits 2,244 21,223 16,404 Accrued expenses 399 544 27 Patents 191 360 443 Stock-based compensation 1,262 1,353 596 Other 202 320 276 6,949 65,956 52,234 Valuation allowance (6,949 ) (65,956 ) (52,234 ) Net deferred tax asset $ - $ - $ - |
Note 12 - Net Loss Per Share 29
Note 12 - Net Loss Per Share Attributable to Common Stockholders (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Year Ended December 31, 2017 2016 2015 Outstanding stock options 2,681,072 2,166,254 2,200,369 Convertible preferred stock 22,112,775 - - 24,793,847 2,166,254 2,200,369 |
Note 13 - Quarterly Financial30
Note 13 - Quarterly Financial Information (Unaudited, in Thousands, Except Share and Per Share Data) (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Quarterly Financial Information [Table Text Block] | Three Months Ended March 31, June 30, September 30, December 31, Operating expenses $ 6,480 $ 5,986 $ 12,306 $ 5,590 Net loss attributable to common stockholders (6,498 ) (5,608 ) (19,054 ) (5,551 ) Net loss per share attributable to common stockholders: Basic and Diluted $ (0.39 ) $ (0.33 ) $ (1.08 ) $ (0.33 ) Weighted-average common shares outstanding used in net loss per share attributable to common stockholders: Basic and Diluted 16,636,201 17,207,672 17,619,418 (a) 17,619,418 Three Months Ended March 31, June 30, September 30, December 31, Operating expenses $ 6,819 $ 7,854 $ 7,166 $ 6,866 Net loss attributable to common stockholders (6,552 ) (7,905 ) (7,107 ) (6,962 ) Net loss per share attributable to common stockholders: Basic and Diluted $ (0.40 ) $ (0.48 ) $ (0.43 ) $ (0.42 ) Weighted-average common shares outstanding used in net loss per share attributable to common stockholders: Basic and Diluted 16,507,586 16,561,239 16,582,276 16,595,502 |
Note 1 - Organization and Ope31
Note 1 - Organization and Operations (Details Textual) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Cash, Cash Equivalents, and Short-term Investments | $ 42,100 | |
Retained Earnings (Accumulated Deficit) | $ (189,741) | $ (159,777) |
Note 2 - Summary of Significa32
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Aug. 02, 2017 | Nov. 12, 2015 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Mar. 31, 2017 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | ||||
Number of Operating Segments | 1 | |||||
Number of Reportable Segments | 1 | |||||
Deferred Tax Assets, Operating Loss Carryforwards | $ 2,651 | $ 42,156 | $ 34,488 | |||
Available-for-sale Securities, Gross Realized Gain (Loss) | 0 | 0 | 0 | |||
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities | 0 | 0 | 0 | |||
Liability for Uncertainty in Income Taxes, Current | 0 | 0 | ||||
Deferred Tax Assets, Valuation Allowance | $ 6,949 | $ 65,956 | $ 52,234 | |||
Accounting Standards Update 2016-09 [Member] | ||||||
Deferred Tax Assets, Operating Loss Carryforwards | $ 600 | |||||
Deferred Tax Assets, Valuation Allowance | $ 600 | |||||
Series A Convertible Preferred Stock [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 22,000 | |||||
Payments of Stock Issuance Costs | $ 500 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | |||
Shares Issued, Price Per Share | $ 1,000 | |||||
Proceeds from Issuance of Convertible Preferred Stock | $ 22,000 | |||||
Common Stock [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 896,811 | |||||
Sales Agreement [Member] | Cowen and Company, LLC [Member] | Common Stock [Member] | ||||||
Sale of Stock, Maximum Value of Stock Offered | $ 40,000 | |||||
Sale of Stock, Commission to Sales Agent, Percentage | 3.00% | |||||
Stock Issued During Period, Shares, New Issues | 896,811 | |||||
Proceeds from Issuance of Common Stock | $ 1,400 | |||||
Payments of Stock Issuance Costs | $ 100 |
Note 2 - Summary of Significa33
Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details) | 12 Months Ended |
Dec. 31, 2017 | |
Computer Equipment and Software [Member] | |
Property and equipment, useful life (Year) | 3 years |
Furniture and Fixtures [Member] | |
Property and equipment, useful life (Year) | 5 years |
Laboratory Equipment [Member] | |
Property and equipment, useful life (Year) | 7 years |
Note 3 - Fair Value Measureme34
Note 3 - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Total | $ 32,633 | $ 33,801 |
Cash Equivalents [Member] | ||
Cash equivalents | 11,662 | 28,876 |
US Government Agencies Debt Securities [Member] | ||
Government securities | 20,971 | 4,925 |
Fair Value, Inputs, Level 1 [Member] | ||
Total | 32,633 | 33,801 |
Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | 11,662 | 28,876 |
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities | 20,971 | 4,925 |
Fair Value, Inputs, Level 2 [Member] | ||
Total | ||
Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | ||
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities | ||
Fair Value, Inputs, Level 3 [Member] | ||
Total | ||
Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | ||
Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities |
Note 3 - Fair Value Measureme35
Note 3 - Fair Value Measurements - Available-for-sale Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Amortized Cost | $ 20,991 | $ 4,924 |
Unrealized Gains | 1 | |
Unrealized Losses | (20) | |
Fair Value | 20,971 | 4,925 |
US Government Agencies Debt Securities [Member] | ||
Amortized Cost | 20,991 | 4,924 |
Unrealized Gains | 1 | |
Unrealized Losses | (20) | |
Fair Value | $ 20,971 | $ 4,925 |
Note 5 - Property and Equipme36
Note 5 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Depreciation | $ 148 | $ 123 | $ 57 |
Note 5 - Property and Equipme37
Note 5 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Property and equipment | $ 971 | $ 937 |
Accumulated depreciation | (712) | (565) |
Property and equipment, net | 259 | 372 |
Computer Equipment and Software [Member] | ||
Property and equipment | 192 | 141 |
Furniture and Fixtures [Member] | ||
Property and equipment | 302 | 318 |
Laboratory Equipment [Member] | ||
Property and equipment | $ 477 | $ 478 |
Note 6 - Accrued Expenses - Acc
Note 6 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 |
Payroll and employee-related costs | $ 1,318 | $ 1,139 |
Contracted service costs | 7,218 | 2,891 |
Professional fees and other | 413 | 493 |
Total | $ 8,949 | $ 4,523 |
Note 7 - Commitments and Cont39
Note 7 - Commitments and Contingencies (Details Textual) SFr in Millions | 1 Months Ended | 12 Months Ended | |||||
Jun. 30, 2018 | Aug. 31, 2017ft² | Feb. 28, 2002 | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2017CHF (SFr) | |
Royalty Payment, Percentage of Net Sales | 2.50% | ||||||
Operating Leases, Increase in Office Space | ft² | 2,552 | ||||||
Area of Real Estate Property | ft² | 7,500 | ||||||
Lessee, Operating Lease, Renewal Term | 1 year | ||||||
Operating Leases, Notice Required to Extend Term | 180 days | ||||||
Operating Leases, Rent Expense | $ 200,000 | $ 200,000 | $ 200,000 | ||||
Security Deposit | 22,000 | ||||||
Letters of Credit Outstanding, Amount | 22,000 | 14,000 | |||||
Loans Pledged as Collateral | 22,000 | $ 14,000 | |||||
Scenario, Forecast [Member] | |||||||
Lessee, Operating Lease, Term of Contract | 1 year 90 days | ||||||
Inventories, Four Batches [Member] | |||||||
Purchase Commitment, Amount Executed | $ 7,800,000 | SFr 7.6 |
Note 7 - Commitments and Cont40
Note 7 - Commitments and Contingencies - Future Minimum Payments for Operating Leases (Details) $ in Thousands | Dec. 31, 2017USD ($) |
2,018 | $ 270 |
2,019 | 207 |
Total minimum lease payments | $ 477 |
Note 8 - Series A Preferred F41
Note 8 - Series A Preferred Financing (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Aug. 02, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | ||
Accretion of Redeemable Convertible Preferred Stock to Redemption Value | $ 6,747 | |||
Series A Convertible Preferred Stock [Member] | ||||
Stock Issued During Period, Shares, New Issues | 22,000 | |||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | |
Shares Issued, Price Per Share | $ 1,000 | |||
Proceeds from Issuance of Convertible Preferred Stock | $ 22,000 | |||
Payments of Stock Issuance Costs | $ 500 | |||
Convertible Preferred Stock, Shares Issued upon Conversion | 1,005 | |||
Convertible Preferred Stock, Conversion Price of Shares Issued upon Conversion | $ 0.9949 | |||
Convertible Preferred Stock, Maximum Ownership Percentage Allowed after Conversion of Stock | 9.985% | |||
Preferred Stock, Redemption Price Per Share | $ 1.30 | |||
Accretion of Redeemable Convertible Preferred Stock to Redemption Value | $ 6,700 | |||
Preferred Stock, Liquidation Preference Per Share | $ 0.001 |
Note 9 - Common Stock (Details
Note 9 - Common Stock (Details Textual) - $ / shares | Dec. 31, 2017 | Dec. 31, 2016 |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares, Issued | 17,674,729 | 16,603,559 |
Common Stock, Shares, Outstanding | 17,674,729 | 16,603,559 |
Note 9 - Common Stock - Common
Note 9 - Common Stock - Common Stock Reserved for Future Issuance (Details) - shares | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2014 |
Reserved for future issuance (in shares) | 25,877,695 | 3,275,291 | |
The 2014 Employee Stock Purchase Plan [Member] | |||
Reserved for future issuance (in shares) | 192,463 | 292,821 | 140,500 |
Performance Shares [Member] | |||
Reserved for future issuance (in shares) | 3,572,457 | 2,982,470 | |
Conversion of Series A Preferred Stock to Common Stock [Member] | |||
Reserved for future issuance (in shares) | 22,112,775 |
Note 10 - Stock-based Compens44
Note 10 - Stock-based Compensation (Details Textual) - USD ($) | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 5 years 328 days | |||
Allocated Share-based Compensation Expense | $ 3,227,000 | $ 3,343,000 | $ 2,164,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 719,337 | 132,495 | 1,010,256 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.99 | $ 5.08 | $ 9.34 | |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 1.99 | $ 7.11 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 27,000 | $ 600,000 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 4,200,000 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 346 days | |||
Common Stock, Capital Shares Reserved for Future Issuance | 25,877,695 | 3,275,291 | ||
Employee Stock Option [Member] | Non-Employees [Member] | ||||
Allocated Share-based Compensation Expense | $ 0 | $ 0 | $ 2,000 | |
The 2014 Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 704,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award Number of Annual Additional Shares Percentage | 4.00% | |||
The 2014 Plan [Member] | Minimum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | |||
The 2014 Plan [Member] | Maximum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||
The 2006 Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 10 years | |||
The 2014 Employee Stock Purchase Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 304,991 | |||
Share-based Compensation Arrangement by Share-based Payment Award Number of Annual Additional Shares Percentage | 1.00% | |||
Allocated Share-based Compensation Expense | $ 100,000 | $ 100,000 | ||
Common Stock, Capital Shares Reserved for Future Issuance | 192,463 | 292,821 | 140,500 | |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 100,358 | 4,538 | ||
The 2014 Employee Stock Purchase Plan [Member] | Maximum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 281,000 |
Note 10 - Stock-based Compens45
Note 10 - Stock-based Compensation - Stock-based Compensation Expense Recognized for Stock Options Granted (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Allocated share-based compensation | $ 3,227 | $ 3,343 | $ 2,164 |
Research and Development Expense [Member] | |||
Allocated share-based compensation | 1,109 | 1,114 | 650 |
General and Administrative Expense [Member] | |||
Allocated share-based compensation | $ 2,118 | $ 2,229 | $ 1,514 |
Note 10 - Stock-based Compens46
Note 10 - Stock-based Compensation - Black-scholes Valuation Assumptions (Details) | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Weighted average expected volatility | 94.50% | 84.40% | 79.80% |
Expected term (in years) (Year) | 6 years 21 days | 6 years 18 days | 6 years 40 days |
Risk free interest rate | 2.09% | 1.45% | 1.76% |
Expected dividend yield | 0.00% | 0.00% | 0.00% |
Note 10 - Stock-based Compens47
Note 10 - Stock-based Compensation - Stock Option Activity for Employees and Non-employees (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||
Options Outstanding, Beginning Balance (in shares) | 2,166,254 | |||
Options Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share) | $ 8.55 | |||
Options Outstanding, Weighted-average Remaining Contractual Term, Beginning Balance (Year) | 6 years 292 days | 7 years 36 days | ||
Options Outstanding, Aggregate Intrinsic Value, Beginning Balance | $ 121 | $ 124 | ||
Options Granted (in shares) | 719,337 | 132,495 | 1,010,256 | |
Options Granted, Weighted Average Exercise Price (in dollars per share) | $ 1.99 | $ 7.11 | ||
Options Exercised (in shares) | (74,001) | |||
Options Exercised, Weighted Average Exercise Price (in dollars per share) | $ 1.45 | |||
Options Forfeited (in shares) | (30,272) | |||
Options Forfeited, Weighted Average Exercise Price (in dollars per share) | $ 10.69 | |||
Options Expired (in shares) | (100,246) | |||
Options Expired, Weighted Average Exercise Price (in dollars per share) | $ 2.60 | |||
Options Outstanding, Ending Balance (in shares) | 2,681,072 | 2,166,254 | ||
Options Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 7.18 | $ 8.55 | ||
Options Exercisable (in shares) | 1,495,789 | |||
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 8.18 | |||
Options Exercisable, Weighted-average Remaining Contractual Term (Year) | 5 years 328 days | |||
Options Exercisable, Aggregate Intrinsic Value | $ 85 | |||
Options Vested or Expected to Vest (in shares) | [1] | 2,681,072 | ||
Options Vested or Expected to Vest, Weighted Average Exercise Price (in dollars per share) | [1] | $ 7.18 | ||
Options Vested or Expected to Vest, Weighted-average Remaining Contractual Term (Year) | [1] | 6 years 292 days | ||
Options Vested or Expected to Vest, Aggregate Intrinsic Value | [1] | $ 121 | ||
[1] | Represents the number of vested options at December 31, 2017 plus the number of unvested options expected to vest based on the unvested options outstanding at December 31, 2017. |
Note 11 - Income Taxes (Details
Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands | Aug. 02, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Mar. 31, 2017 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 34.00% | |||||
Deferred Tax Assets, Increase (Decrease) from Revaluation Due to Tax Rate Change | $ (2,200) | |||||
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability | 0 | |||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (54,100) | $ 8,800 | $ 9,800 | |||
Operating Loss Carryforwards | $ 0 | |||||
Tax Credit Carryforward, Amount | 0 | 2,300 | 21,800 | 16,900 | ||
Unrecognized Tax Benefits | 0 | 0 | 0 | |||
Deferred Tax Assets, Valuation Allowance | 6,949 | 65,956 | 52,234 | |||
Deferred Tax Assets, Valuation Allowance, Increase (Decrease) from Revaluation Due to Tax Rate Change | (2,200) | |||||
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | 0 | 0 | 0 | |||
Deferred Tax Assets, Operating Loss Carryforwards | 2,651 | 42,156 | 34,488 | |||
Accounting Standards Update 2016-09 [Member] | ||||||
Deferred Tax Assets, Valuation Allowance | $ 600 | |||||
Deferred Tax Assets, Operating Loss Carryforwards | $ 600 | |||||
Current Year Deferred Tax Assets Activity [Member] | ||||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 13,100 | |||||
Effect on Deferred Tax Assets of Section 382 Limitation [Member] | ||||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (65,000) | |||||
Effect of Tax Rate Change on Deferred Tax Assets [Member] | ||||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (2,200) | |||||
Series A Preferred Stock [Member] | ||||||
Proceeds from Issuance of Convertible Preferred Stock | 22,000 | |||||
Scenario, Forecast [Member] | ||||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | |||||
Domestic Tax Authority [Member] | ||||||
Income Tax Expense (Benefit) | 0 | 0 | 0 | |||
Operating Loss Carryforwards | 10,600 | 101,400 | 94,200 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | ||||||
Decrease in Net Operating Loss Carryforwards from Section 382 Limitation | 107,300 | |||||
Decrease in Net Operating Loss Carryforwards from Section 382 Limitation, Tax Affected | 34,100 | |||||
Decrease in Tax Credit Carryforward Amount from Section 382 Limitation | 23,800 | |||||
State and Local Jurisdiction [Member] | ||||||
Income Tax Expense (Benefit) | 0 | 0 | 0 | |||
Decrease in Net Operating Loss Carryforwards from Section 382 Limitation | 5,000 | |||||
Decrease in Tax Credit Carryforward Amount from Section 382 Limitation | $ 2,100 | |||||
Operating Loss Carryforwards | $ 6,800 | $ 53,000 | $ 46,400 |
Note 11 - Income Taxes - Domest
Note 11 - Income Taxes - Domestic and Foreign Loss Before Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Domestic | $ (24,803) | $ (15,860) | $ (21,377) |
Foreign | (5,161) | (12,666) | |
Loss before income taxes | $ (29,964) | $ (28,526) | $ (21,377) |
Note 11 - Income Taxes - Reconc
Note 11 - Income Taxes - Reconciliation of Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Income tax benefit using U.S. federal statutory rate | $ (10,186) | $ (9,696) | $ (7,315) |
Permanent differences | 4 | 430 | 260 |
Stock Compensation - Perm Items | 689 | ||
R&D Credit -Perm Items | 1,751 | 1,437 | 1,310 |
State income taxes, net of federal benefit | (853) | (498) | (808) |
Tax credits | (5,495) | (4,846) | (4,219) |
Change in valuation allowance | (54,319) | 8,804 | 9,782 |
Foreign rate differential | 1,752 | 4,304 | |
Rate change | 2,202 | ||
382 Limitation | 64,975 | ||
Other | $ (520) | $ 65 | $ 990 |
Note 11 - Income Taxes - Summar
Note 11 - Income Taxes - Summary of Deferred Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Deferred Tax Assets, Operating Loss Carryforwards | $ 2,651 | $ 42,156 | $ 34,488 |
Federal and state tax credits | 2,244 | 21,223 | 16,404 |
Accrued expenses | 399 | 544 | 27 |
Patents | 191 | 360 | 443 |
Stock-based compensation | 1,262 | 1,353 | 596 |
Other | 202 | 320 | 276 |
6,949 | 65,956 | 52,234 | |
Valuation allowance | (6,949) | (65,956) | (52,234) |
Net deferred tax asset | $ 0 | $ 0 | $ 0 |
Note 12 - Net Loss Per Share 52
Note 12 - Net Loss Per Share Attributable to Common Stockholders - Common Stock Equivalents Excluded From Calculation of Net Loss Per Share (Details) - shares | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Antidilutive Securities (in shares) | 24,793,847 | 2,166,254 | 2,200,369 |
Convertible Preferred Stock [Member] | |||
Antidilutive Securities (in shares) | 22,112,775 | ||
Employee Stock Option [Member] | |||
Antidilutive Securities (in shares) | 2,681,072 | 2,166,254 | 2,200,369 |
Note 13 - Quarterly Financial53
Note 13 - Quarterly Financial Information (Unaudited, in Thousands, Except Share and Per Share Data) - Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | ||
Total operating expenses | $ 5,590 | $ 12,306 | $ 5,986 | $ 6,480 | $ 6,866 | $ 7,166 | $ 7,854 | $ 6,819 | $ 30,362 | $ 28,705 | $ 20,870 | |
Net loss attributable to common stockholders | $ (5,551) | $ (19,054) | $ (5,608) | $ (6,498) | $ (6,962) | $ (7,107) | $ (7,905) | $ (6,552) | ||||
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) | $ (0.33) | $ (1.08) | $ (0.33) | $ (0.39) | $ (0.42) | $ (0.43) | $ (0.48) | $ (0.40) | $ (2.13) | $ (1.72) | $ (1.30) | |
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted (in shares) | 17,619,418 | 17,619,418 | [1] | 17,207,672 | 16,636,201 | 16,595,502 | 16,582,276 | 16,561,239 | 16,507,586 | 17,274,326 | 16,561,799 | 16,464,123 |
[1] | Adjusted to correct an immaterial error in the weighted-average share calculation in the Company's Form 10-Q as of September 30, 2017. |